The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N02 | Analgesics | |
| 3 | N02C | Antimigraine preparations | |
| 4 | N02CD | Calcitonin gene-related peptide (CGRP) antagonists | |
| 5 | N02CD03 |
| Active Ingredient | Description | |
|---|---|---|
| Fremanezumab |
Fremanezumab is a humanised IgG2Δa/kappa monoclonal antibody which selectively binds the calcitonin gene-related peptide (CGRP) ligand and blocks both CGRP isoforms (α- and β-CGRP) from binding to the CGRP receptor. It is believed that prevention of migraine is obtained by its effect modulating the trigeminal system. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| AJOVY Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
